Heteroclitic peptide cancer vaccine counters MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms

Autor: Gigoux, Mathieu, Zappasodi, Roberta, Park, Joseph J, Pourpe, Stephane, Ghosh, Arnab, Bozkus, Cansu Cimen, Mangarin, Levi M.B., Redmond, David, Svena Verma, Svena, Sara Schad, Sara, Duke, William, Leventhal, Matthew, Jan, Max, Ho, Vincent, Hobbs, Gabriella, Knudsen, Trine Alma, Skov, Vibe, Kjær, Lasse, Larsen, Thomas Stauffer, Lund Hansen, Dennis, Coleman Lindsley, R, Hasselbalch, Hans C., Grauslund, Jacob H., Mads H Andersen, Mads H, Holmström, Morten O, Chan, Timothy, Rampal, Raajit, Abdel-Wahab, Omar, Nina Bhardwaj, Nina, Wolchok, Jedd D, Mullally, Ann, Merghoub, Taha

Publikováno v: Gigoux, M, Zappasodi, R, Park, J J, Pourpe, S, Ghosh, A, Bozkus, C C, Mangarin, L M B, Redmond, D, Svena Verma, S, Sara Schad, S, Duke, W, Leventhal, M, Jan, M, Ho, V, Hobbs, G, Knudsen, T A, Skov, V, Kjær, L, Larsen, T S, Lund Hansen, D, Coleman Lindsley, R, Hasselbalch, H C, Grauslund, J H, Mads H Andersen, M H, Holmström, M O, Chan, T, Rampal, R, Abdel-Wahab, O, Nina Bhardwaj, N, Wolchok, J D, Mullally, A & Merghoub, T 2020, ' Heteroclitic peptide cancer vaccine counters MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms ', Journal of Immunology, vol. 204, no. Suppl. 1, 239.34 . < https://www.jimmunol.org/content/204/1_Supplement/239.34 >

The majority of JAK2WT myeloproliferative neoplasms (MPN) have disease-initiating frameshift mutations in calreticulin (CALR) resulting in a common novel C-terminal mutant fragment (CALRMUT), representing an attractive source of neoantigens for cance

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c1341674b2143716aa75f2e3dda8759
https://doi.org/10.4049/jimmunol.204.supp.239.34